

Robert A. Hatcher, M.D.

Gary K. Stewart, M.D.

Felicia Stewart, M.D.

Felicia Guest

Pamela Stratton

Angela H. Wright

# CONTRACEPTIVE TECHNOLOGY 1978-1979

9th Revised Edition



# UPDATE: New developments as we go to press

## Pregnancy Tests, Chapter 15

E.p.t. (early pregnancy test), a do-it-yourself pregnancy test for home use, was marketed in early 1978. It is a two-hour urine test similar to the assays described in our chapter, and costs \$10-12. It has the *advantage* of offering patients privacy to determine for themselves whether or not they are pregnant, and the *disadvantage* that a pelvic exam to determine the number of weeks pregnancy may not be pursued by all patients. As with many pregnancy tests, there is a high incidence of false negative tests in early pregnancy.

## Contraceptive Effectiveness, Chapter 1

A new contraceptive effectiveness study appeared in 1977. "Contraceptive Failure Among Married Women in the United States, 1970-1973" by B. Vaughn, J. Trussell, J. Menken, and E.F. Jones, *Family Planning Perspectives*, Volume 9, Number 6, November/December 1977, is a useful addition to our understanding of method effectiveness (life table calculations) for delayers and preventers.

## Combination Oral Contraceptives, Chapter 4

The prospective oral contraceptive studies from England give cause for increasing concern about risks of long-term use of oral contraceptives. Beral (*Lancet*, October 1977) reported an *excess death rate* of 20/100,000 among women who had ever used oral contraceptives. This is a far greater excess risk than previous reports that surveyed vascular disease as a Pill-related cause of death. Further, vascular effects *persist* after Pills are discontinued. The significance of these findings for U. S. Pill users is not yet clear.

In April, 1978 the FDA required that detailed labeling information for patients be given with each supply of Pills—another step towards fully informing patients.

## Progestin-Only Contraceptive, Chapter 5

Depo-Provera was *rejected* by the FDA for use as a long-acting contraceptive in the U.S.A. in March-April, 1978.

## **Natural Family Planning, Chapter 10**

The official Catholic community has begun an active involvement in family planning with their acceptance of natural family planning. Creative approaches for teaching, evaluating, and practicing the natural methods are proliferating.

## **Spermicidal Foam and Encare Oval, Chapter 9**

Concern has been raised over the effectiveness rates of the newly marketed Encare Oval, a vaginal suppository which melts, then foams to release nonoxynol 9. Effectiveness rates cited by the Oval manufacturer are derived from a very unconventional study design. Careful effectiveness studies are needed. Meanwhile, the authors believe the safest approach is to consider the Oval on a par with foam for effectiveness.

Robert A. Hatcher, M.D.

Gary K. Stewart, M.D.

Felicia Stewart, M.D.

Felicia Guest

Pamela Stratton

Angela H. Wright

# CONTRACEPTIVE TECHNOLOGY 1978-1979

9th Revised Edition

IRVINGTON PUBLISHERS, INC., New York

---

HALSTED PRESS Division of  
JOHN WILEY & SONS

New York

London

Sidney

Toronto

Copyright © 1978 by Irvington Publishers, Inc.

All rights reserved. No part of this book may be reproduced in any manner whatever, including information storage or retrieval, in whole or in part (except for brief quotations in critical articles or reviews), without written permission from the publisher. For information, write to Irvington Publishers, Inc., 551 Fifth Avenue, New York, New York 10017.

Distributed by HALSTED PRESS,  
A division of JOHN WILEY & SONS, New York

Library of Congress Cataloging in Publication Data  
Main entry under title:

Contraceptive technology, 1976-1977.

Bibliography: p.

1. Conception—Prevention. 2. Birth control.

I. Hatcher, Robert Anthony, 1937-

RG136.C578 613.9'4 75-38887

ISBN 0-470-26360-1

10 9 8 7 6 5 4 3 2

Printed in The United States of America

## Preface and Dedication

This is the ninth edition of *Contraceptive Technology*, and we would like to recognize the contributions of many people who have assisted us in this effort to provide up-to-date information about family planning.

On the inside cover, you will find a long list, by state, of the people whose ideas and efforts, corrections and suggestions have made this book what it is. Birth control technology changes rapidly, and *Contraceptive Technology* has evolved with the help of many fine people. In particular, we would like to thank Dr. Ward Cates of Atlanta and Dr. Jack Lipkes of Buffalo for their extensive help in preparing this edition of *Contraceptive Technology*.

Here are the two most important changes in our book this year:

1. Chapter 22 presents new material on contraceptive interactions. This chapter goes into the nutritional effects of family planning, outlines a vast array of biochemical changes (alterations in laboratory values) produced by contraceptives, and describes drugs that may diminish the effectiveness of oral contraceptives if taken simultaneously (such as Dilantin and Rifampicin).

2. The book has been divided into what we hope is a more logical approach to birth control technology. Section I deals with the technology of contraception, abortion, and sterilization. Section II covers several topics pertaining to the humane delivery of fertility control services.

We would like to dedicate this edition of *Contraceptive Technology* to two individuals who have made vast contributions to the task of defining the limits, the effectiveness, and the risks associated with contraceptive methods that are used today. *Contraceptive Technology 1978-1979* is dedicated to Dr. Christopher Tietze and Sarah Lewit. Christopher Tietze and Sarah Lewit, a husband and wife team, have separately and jointly written more than 200 articles, mostly in the field of human fertility and its regulation. Christopher Tietze, a native of Austria with an M.D. from the University of Vienna, came to this country in 1938. He has worked for the Johns Hopkins University School of Hygiene and Public Health, the U.S. Department of State, and the National Committee on Maternal Health. He is currently a Senior Fellow at the Population Council's Center for Policy Studies. Sarah Lewit, a graduate of Brooklyn College, was employed by the Department of Health, Education and Welfare and by the National Committee on Maternal Health before she joined the Population Council in 1967 as a Research Associate. Since 1973, she has worked as a freelance v

writer. Tietze and Lewit were co-recipients of Planned Parenthood's Margaret Sanger Award in 1973.

As many have done before and as many will do in the future, our message to Christopher Tietze and Sarah Lewit is simple but heartfelt: Thank you.

Robert A. Hatcher, M.D.

Gary K. Stewart, M.D.



The photograph of Dr. Christopher Tietze and Sarah Lewit was taken by Robert Gilbert, New York City, N.Y.

## **CONTENTS**

PREFACE AND DEDICATION	v
FIGURES	xii
TABLES	xiii
INTRODUCTION: PRINCIPLES OF FAMILY PLANNING	xiv

### **SECTION I. THE TECHNOLOGY OF CONTRACEPTION**

CHAPTER 1. CONTRACEPTIVE EFFECTIVENESS	19
A. Two Types of Effectiveness: Theoretical and Actual Use Effectiveness	
B. Brief Comments on the Effectiveness of Pills, Mini-Pills, IUD's, Foam, Condoms, and Diaphragms	
C. What Is the Value of the Pearl Index?	
CHAPTER 2. THE MENSTRUAL CYCLE	28
A. Physiology	
B. Menstrual History	
C. Contraceptive Effects on Three Phases of the Menstrual Cycle	
CHAPTER 3. HORMONAL CONTRACEPTIVES: AN OVERVIEW	35
A. History	
B. Mechanisms of Action of Estrogens as Contraceptives	
C. Mechanisms of Action of Progestins as Contraceptives	
CHAPTER 4. COMBINED ORAL CONTRACEPTIVES	37
A. Effectiveness	
B. Contraindications to Estrogen-Containing Pills	
C. Choice of a Combined Oral Contraceptive	
D. Instructions to Patient	
E. Complications	
F. Clinic Procedures in Management of Pill Patients	
G. Non-Contraceptive Benefits	vii



CHAPTER 5. PROGESTIN-ONLY CONTRACEPTIVES 55

- A. The Mini-Pill or Progestin-Only Pills
- B. Post-Coital Progestins
- C. Long-Acting Progesterone Injections (The Shot)
- D. Other Progestins as Contraceptives

CHAPTER 6. INTRAUTERINE DEVICES 62

- A. History
- B. Mechanism of Action
- C. Effectiveness
- D. Types of IUD's
- E. Contraindications to IUD Insertion
- F. Factors to Consider in Choosing an IUD
- G. IUD Insertion
- H. Paracervical Anesthesia or Paracervical Block
  - I. Instructions to Patient
- J. Techniques of Simplifying IUD Removal
- K. Management of Pregnancy with an IUD in Place
- L. Complications from IUD's
- M. Other Clinical Uses of IUD's
- N. Medicated IUD's as Compared to Non-Medicated IUD's

CHAPTER 7. THE DIAPHRAGM 79

- A. Mechanism of Action
- B. Effectiveness
- C. Contraindications
- D. Fitting the Diaphragm
- E. Instructions to Patient
- F. Non-Contraceptive Benefits
- G. Side Effects
- H. Cost (Pharmacy)

CHAPTER 8. THE CONDOM 85

- A. History
- B. Mechanism of Action

- C. Effectiveness
- D. Side Effects
- E. Distribution
- F. Instructions to Patient
- G. Non-Contraceptive Benefits

CHAPTER 9. SPERMICIDAL FOAM 88

- A. Mechanism of Action
- B. Effectiveness
- C. Instructions to Patient
- D. Side Effects
- E. Contraindications
- F. Other Clinical Uses
- G. Cost

CHAPTER 10. RHYTHM 94

- A. Introduction
- B. Calendar Method
- C. Basal Body Temperature Method
- D. Evaluation of Changes in Cervix and Cervical Secretions: Also Called "Natural Birth Control"
- E. Other Considerations
- F. Effectiveness
- G. Side Effects
- H. Other Clinical Uses
- I. Contraindications
- J. Cost

CHAPTER 11. ABSTINENCE 100

CHAPTER 12. COITUS INTERRUPTUS 101

CHAPTER 13. LACTATION 102

CHAPTER 14. POST-COITAL CONTRACEPTION 103

- A. Morning-After Pills
- B. Morning-After IUD Insertion
- C. Menstrual Extraction
- D. Therapeutic Abortion After Diagnosis of Pregnancy
- E. Full-Term Pregnancy

CHAPTER 15. PREGNANCY TESTING	108
CHAPTER. 16. ABORTION	111
A. Legal Status of Abortion	
B. Abortion Decision Making	
C. Abortion Technology and Clinical Management	
D. Abortion Risks and Complications	
E. Follow-up Care Instructions to Patient	
CHAPTER 17. STERILIZATION	126
A. Introduction	
B. Mechanism of Action	
C. Factors Affecting the Utilization of Sterilization	
D. Permanent Contraception for Men	
E. Permanent Contraception for Women	
F. Research	
 <b>SECTION II. PATIENT-ORIENTED CONTRACEPTIVE CARE AND MEDICAL CONCERNS RELATED TO CONTRACEPTION</b>	
CHAPTER 18. HEALTH BENEFITS OF VOLUNTARY FAMILY PLANNING	142
A. Planned Pregnancies	
B. Unplanned Pregnancies	
C. Education and Counseling	
D. Population	
CHAPTER 19. INFORMED CONSENT AND LEGAL CONSIDERATIONS IN FAMILY PLANNING	145
CHAPTER 20. PROBLEM-ORIENTED APPROACH TO FAMILY PLANNING	148

x

CHAPTER 21. MANAGEMENT OF SEXUALLY TRANSMITTED INFECTIONS	148
A. <i>Corynebacterium Vaginalis</i> Vaginitis	
B. Cystitis	
C. Gonorrhea	
D. Herpes Genitalis	
E. Monilia	
F. Pelvic Inflammatory Disease	
G. Pubic Lice	
H. Syphilis	
I. Trichomoniasis	
J. Venereal Warts	
CHAPTER 22. CONTRACEPTIVE INTERACTIONS AND NUTRITIONAL IMPLICATIONS OF FAMILY PLANNING	164
A. Oral Contraceptives	
B. Intrauterine Device	
C. Foam, Jellies, and Creams	
D. Diaphragm	
E. Nutritional Evaluation	
REFERENCES	175
INDEX	185

## FIGURES

- Figure 1: Interrelationships and Feedback Mechanisms Relating to the Human Menstrual Cycle
- Figure 2: The Menstrual Cycle
- Figure 3: Relative Potency of Estrogens and Progestins in Currently Available Oral Contraceptives
- Figure 4: Comparison of the Incidence of Various Conditions in Current Users of Oral Contraceptives, Royal College of General Practitioners, 1968-1971
- Figure 5: Weight Changes in Depo-Provera Patients
- Figure 6: F.D.A. approved IUD's in 1976
- Figure 7: Alligator Forceps for Simplifying IUD Removal
- Figure 8: Basal Body Temperature Variations During a Model Menstrual Cycle
- Figure 9: Pregnancy Alternatives
- Figure 10: Sterilizations for Men and Women Between 1969 and 1976
- Figure 11: Physical Exam Form

## TABLES

- Table 1: Method Effectiveness: Theoretical and Actual Use Rates
- Table 2: Methods of Fertility Control: Factors Affecting Their Utilization
- Table 3: Condom Failure Rates per 100 Woman Years of Exposure in Five Recent United Kingdom Studies
- Table 4: Reasons For Stopping the Pill
- Table 5: Combination, Sequential, and Microdose Progestin Oral Contraceptives Marketed in the United States from 1960-1977
- Table 6: Pill Side Effects: A Time Framework
- Table 7: Pill Side Effects: Hormone Etiology
- Table 8: Physical Characteristics of IUD's, IUD Strings, and IUD Insertion Mechanisms
- Table 9: Choosing an IUD for an Individual Patient
- Table 10: Overview of IUD Effectiveness and Complications
- Table 11: Reported Failure Rates for Spermicidal Foams
- Table 12: How to Calculate the Interval of Fertility
- Table 13: Generic Estrogen Compounds with Brand Names of Marketed Agents and Equivalence to 50 mg/day of DES
- Table 14: Some Immunological Pregnancy Tests
- Table 15: Death-to-Case Rate for Legal Abortions by Type of Procedure, United States, 1972-1975
- Table 16: Death-to-Case Rate for Legal Abortions by Weeks of Gestation, United States, 1972-1975
- Table 17: Classification of Deaths Associated with Legal Abortion by Cause, United States. 1972-1975
- Table 18: Rate and Relative Risk of Selected Complications with Dilatation and Evacuation (D&E) and Saline Instillation (SI)
- Table 19: Number of Patients Aborted by Saline and by Suction
- Table 20: Summary of Medical Complications of Vasectomy
- Table 21: Major Complications of Laparoscopy for Sterilization Among AAGL Members, 1974-1975
- Table 22: Death Risk from Sterilization by Laparoscopy by Year of Procedure as Reported by AAGL
- Table 23: Potential Effects of Oral Contraceptives on the Results of a Selected Group of Laboratory Tests
- Table 24: Desirable Weights for Men and Women According to Height and Frame, Age 25 and Over

## Introduction:

### Principles of Family Planning

We believe that. . .

1. *Voluntary family planning is an important health measure.* The availability or unavailability of services has an enormous impact on the health of an individual, a relationship, a family, a community, and, indeed, an entire nation.

2. *Unless a certain method is contraindicated, patients have a right to make a voluntary, unpressured decision concerning birth control methods.* Practitioners should avoid labeling certain methods as “good” or “bad” or presenting methods in any biased manner.

3. *It is the family planning practitioner’s responsibility to provide thorough information to, and to encourage questions from, the patient.* Each patient has a right to all information necessary for informed consent.

4. *Patients have a right to be treated with dignity in a private setting.* This facilitates frank discussions of embarrassing questions and personal matters and mitigates the fear of examination.

5. *Patients have a right to complete confidentiality in data systems and medical records.*

6. *Family planning practitioners are responsible for providing high quality health education to the community as well as to individual patients.* In order to be responsive to the community, practitioners should cooperate with schools, community groups, and local health programs. Also, there should be communication with the community through use of news media and printed materials.

7. *Each member of society has a right to family planning care regardless of ability to pay or social status.* Family planning is a right of each individual, including teenagers, prisoners, psychiatric patients, and those who are poor.

8. *Birth control, abortion, and sterilization are vital components of a voluntary, comprehensive family planning program.*

9. *Participation of male partners in family planning adds an important dimension to care.* This encourages couples to share responsibility for decisions, widens the scope of the family planning education program, and aids the practitioner in understanding and treating the patient.

10. *Family planning clinics can provide many non-contraceptive services to patients.* We cannot assume that every individual coming to a

xiv family planning clinic is there for contraception. Patients may be there for a

Pap smear, breast examination, treatment of a vaginal infection, V.D. test, or evaluation of an infertility problem. They may be practicing abstinence and may have no current need for contraception.

11. *The family planning clinic can facilitate the entry of individuals into other components of the health care system.*

12. *Population concerns should not be the major focus or objective in a family planning clinic.* Our patients for the most part do not come for services out of concern for world population pressures. Patients may be antagonized by the association of their medical clinics with efforts to achieve population stabilization.\*

\*This principle, discouraging population education within a family planning clinic, has been criticized repeatedly by readers of *Contraceptive Technology* who feel that population education should occur in the family planning clinic setting. The authors of *Contraceptive Technology 1978-79* unanimously agree that population pressures are already significantly diminishing the quality of life on this little spaceship called earth. We all would like to see population stabilization. The question is WHERE should population education occur? We obtained extensive comments from individuals on our patient advisory committees and from employees of family planning programs. Several comments opposed to population education in the clinic setting by patients and staff are noteworthy:

"There is a population explosion, but people come to the clinic for personal reasons."

"I personally feel that discussion of population problems in our clinic would be a waste of time."

"I personally feel that population concerns have no place in a family planning clinic. I think our patients come here for medical services not to hear or read about how many people are in the world."

"If you discuss population in the family planning clinic with written material, posters, or personal comments, the wrong person, that is, a militant person, might get hold of it and cause trouble."



